Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents-Reference-Cited by-同舟云学术

Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents

Published:2012-09-07 Issue:2 Volume:31 Page:96-102
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematol Oncol

Author:

Maltezas Dimitrios¹,Dimopoulos Meletios A.¹,Katodritou Irene¹,Repousis Panagiotis¹,Pouli Anastasia¹,Terpos Evangelos¹,Panayiotidis Panayiotis¹,Delimpasi Sossana¹,Michalis Evridiki¹,Anargyrou Konstantinos¹,Gavriatopoulou Maria¹,Stefanoudaki Aikaterini¹,Tzenou Tatiana¹,Koulieris Efstathios¹,Sachanas Sotiris¹,Dimou Maria¹,Vassilakopoulos Theodoros P.¹,Angelopoulou Maria K.¹,Pangalis Gerassimos A.¹,Kyrtsonis Marie-Christine

Affiliation:

1. Hellenic Myeloma Study Group; Athens; Greece

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hon.2026/fullpdf

Reference33 articles.

1. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival;Durie;Cancer,1975

2. International Staging System for multiple myeloma;Greipp;J Clin Oncol,2005

3. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system;Durie;Eur J Cancer,2006